Fortress Biotech (FBIO) Stock Price, News & Analysis

Company Overview

Fortress Biotech, Inc. is a clinical‐stage biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Headquartered in New York, the company operates through a network of majority‐owned subsidiaries that target areas of high unmet medical need, including oncology, rare diseases and dermatology. Fortress Biotech’s business model emphasizes in‐licensing or acquiring promising drug candidates and coordinating their development through specialized affiliate companies, allowing for flexible capital allocation and focused management of individual programs.

Through its portfolio of subsidiaries, Fortress Biotech advances a diversified pipeline spanning small molecules, biologics and cell therapies. Its affiliates include companies developing immuno‐oncology therapies, gene and cell therapy approaches for genetic and rare disorders, as well as topical and systemic dermatology products. By leveraging internal expertise and external partnerships, the company seeks to optimize trial design, regulatory strategy and commercialization pathways for each candidate, aiming to accelerate time to market and enhance value creation.

Founded in 2007 by Pablo Legorreta, Fortress Biotech completed its initial public offering under the name Coronado Biosciences before rebranding to its current identity in 2016. Over more than a decade, the company has cultivated relationships with leading academic institutions, contract research organizations and commercial partners to support global clinical development and eventual product launches. While its primary operations are based in the United States, Fortress Biotech’s programs often involve international trial sites and regulatory filings across North America and Europe.

Under the leadership of Chairman and Chief Executive Officer Pablo Legorreta, Fortress Biotech maintains a strategic focus on unlocking the potential of under‐resourced programs. By structuring development efforts through dedicated subsidiaries, the company aims to balance risk and reward, fostering innovation across multiple therapeutic areas while preserving the flexibility to collaborate with larger pharmaceutical and biotechnology firms.

Key Stats

• Today's Range: $2.57 to $2.69
• 50-Day Range: $2.22 to $3.36
• 52-Week Range: $1.67 to $4.53
• Volume: 390,600 shs
• Average Volume: 336,951 shs
• Market Capitalization: $88.03 million
• P/E Ratio: 0.84
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Hold

Fortress Biotech Stock Analysis - MarketRank™

Fortress Biotech scored higher than 82% of companies evaluated by MarketBeat, and ranked 120th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

Fortress Biotech has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Fortress Biotech has a consensus price target of $17.00, representing about 541.5% upside from its current price of $2.65.

Amount of Analyst Coverage

Fortress Biotech has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 143.55%

Earnings Growth

Earnings for Fortress Biotech are expected to grow by 143.55% in the coming year, from $0.62 to $1.51 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fortress Biotech is 0.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.53.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fortress Biotech is 0.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.82.

Price to Book Value per Share Ratio

Fortress Biotech has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.58% of the float of Fortress Biotech has been sold short.

Short Interest Ratio / Days to Cover

Fortress Biotech has a short interest ratio ("days to cover") of 17.78, which indicates bearish sentiment.

Change versus previous month

Short interest in Fortress Biotech has recently increased by 2.26%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fortress Biotech does not currently pay a dividend.

Dividend Growth

Fortress Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.38

News Sentiment

Fortress Biotech has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Fortress Biotech this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for FBIO on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.

MarketBeat Follows

3 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fortress Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.50% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 5/21/2026
• AGM 2026: 6/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FBIO
• CIK: 1429260
• Web: www.fortressbiotech.com
• Phone: (781) 652-4500
• Fax: 781-652-4545
• Employees: 170
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Fortress Biotech: $17.00
• High Price Target: $17.00
• Low Price Target: $17.00
• Potential Upside/Downside: +541.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.17
• Trailing P/E Ratio: 0.84
• Forward P/E Ratio: 4.27
• P/E Growth: N/A
• Net Income: $6.82 million
• Net Margins: 193.12%
• Pretax Margin: 201.71%
• Return on Equity: 109.66%
• Return on Assets: 45.56%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 2.86
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: $63.26 million
• Price / Sales: 1.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.09 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 33,220,000
• Free Float: 23,752,000
• Market Cap: $88.03 million
• Optionable: Optionable
• Beta: 1.16